BioSpace News Archive

The oral medication for Infantile spasms (IS) is in phase 2 clinical trials in Korea and the US, and the IV medication for Status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2) by expanding R&D through an IPO [26-March-2020] SUWON, S

The U.S. Department of Health and Human Services, American Society of Nephrology and National Kidney Foundation announced that 25 innovators have been selected as winners in two categories of the first-ever KidneyX: Patient Innovator Challenge, funded by NKF.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), announced today that the Company’s CEO Dr. Stuart Titus was featured in global financial news outlet Reuters discussing the impact of COVID-19 on the cannabis industry.

Micro Video Instruments Inc. (MVI) and Morrell Instrument Company will continue as authorized Nikon dealers for Clinical, Educational, Industrial and Materials markets [26-March-2020] MELVILLE, N.Y. , March 26, 2020 /PRNewswire/ -- Nikon Instruments Inc., innovator of advanced microscope systems, today announced that it will assume direct representation for all Resear

- VGX-3100 DNA medicine cleared high-risk HPV 16/18-associated precancerous lesions in 50% of patients, and reduced the number of lesions in 75% of patients - Data to be presented at the 2020 American Society for Colposcopy and Cervical Pathology (ASCCP) meeting [26-March-2020] PLYMOUTH MEETING, Pa. , March 26, 2020 /PRNewswire/ -- INOVIO Pharmaceuticals, In

March 2020 issue of AAC journal highlights in vitro study at MD Anderson Cancer Center Labs that shows Mino-Lok to be effective in completely eradicating all ten strains of Candida auris tested [26-March-2020] CRANFORD, N.J. , March 26, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a specialty pharmaceutical company focu

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled “Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease” at the National Kidney Foundation (NKF) 2020 Spring Clinical Meetings Live Virtual Conference. For information about the virtual event, visit:

Benitec Biopharma announced that in accordance with Australian Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001, the shareholder resolution to redomicile Benitec to the USA was passed.

BioInvent International AB (“BioInvent”) (OMXS: BINV) today announces that the Board of Directors has resolved to postpone the annual general meeting until May 28, 2020.

Orphan Technologies, a company dedicated to helping patients control their homocysteine levels, today announced that OT-58 for the treatment of cystathionine beta synthase deficiency homocystinuria has been designated a rare pediatric disease (RPD) by the US Food and Drug Administration (FDA). Under the RPD program, if a new drug application for OT-58 is approved,